Ghisallo Capital Management’s Roivant Sciences ROIV Stock Holding History

Ghisallo Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,500	Closed	-$540K	–	364
2026 Q1	$540K	Buy	+19,500	New	+$501K	0.01%	251
2023 Q4	–	Sell	-400,000	Closed	-$4.67M	–	162
2023 Q3	$4.67M	Buy	400,000 +150,000	+60%	+$1.7M	0.48%	46
2023 Q2	$2.52M	Hold	250,000	–	–	0.3%	65
2023 Q1	$1.84M	Buy	+250,000	New	+$2.06M	0.44%	41

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Ghisallo Capital Management's ROIV Position: Q2 2026 in Review

Ghisallo Capital Management sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 19,500 shares — an estimated $540K sold.

Ghisallo Capital Management first reported a position in ROIV in Q1 2023 and held it in 4 quarters. The position peaked at $4.67M in Q3 2023. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Ghisallo Capital Management reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Ghisallo Capital Management sold 19,500 Roivant Sciences shares in Q2 2026, an estimated $540K.
Ghisallo Capital Management first reported a position in Roivant Sciences in Q1 2023 and held it in 4 quarters.
Ghisallo Capital Management's Roivant Sciences position peaked at $4.67M in Q3 2023.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.